Great report takeaway: Valuation range of A$0.016-A$0.021 per share
We continue to value Invion at A$0.016-A$0.021 per share
using a weighted DCF approach. Although Invion’s valuation
has retreated from the highs of 2021, along with the broader
biotechnology sector, we believe that Invion has the potential
to re-rate as the clinical development of INV043 de-risks its
future prospects. Please see page 11 for key risks.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.6¢ |
Change
-0.004(4.00%) |
Mkt cap ! $8.199M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.6¢ | $5.005K | 50.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 75868 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 278199 | 3 |
View Market Depth
| Last trade - 15.03pm 31/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |